SNRI ‘Shows Promise’ for Comorbid ADHD, PTSD

 ADHD in the News 2021-03-25

Atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), may improve outcomes for patients with both attention-deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD), new research suggests. A pilot trial of veterans with comorbid ADHD/PTSD showed that atomoxetine significantly reduced ADHD symptoms and moderately improved PTSD treatment outcomes and quality of life in comparison with placebo.